Exact Sciences Corp EXAS
We take great care to ensure that the data presented and summarized in this overview for EXACT SCIENCES CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EXAS
View all-
Capital World Investors Los Angeles, CA17.5MShares$831 Million0.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA17MShares$807 Million0.02% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$572 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA12.1MShares$572 Million0.13% of portfolio
-
State Street Corp Boston, MA6.23MShares$295 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.76MShares$273 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.27MShares$202 Million0.15% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN4.21MShares$200 Million0.06% of portfolio
-
Jpmorgan Chase & CO New York, NY3.49MShares$166 Million0.02% of portfolio
-
William Blair Investment Management, LLC Chicago, IL3.44MShares$163 Million0.51% of portfolio
Latest Institutional Activity in EXAS
Top Purchases
Top Sells
About EXAS
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Insider Transactions at EXAS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 25
2025
|
Kevin T Conroy President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,195
-0.55%
|
$315,945
$51.28 P/Share
|
|
Feb 25
2025
|
Kevin T Conroy President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,180
+1.16%
|
-
|
|
Feb 25
2025
|
Jacob A Orville EVP, GM, Screening |
SELL
Payment of exercise price or tax liability
|
Direct |
1,859
-8.4%
|
$94,809
$51.28 P/Share
|
|
Feb 25
2025
|
Jacob A Orville EVP, GM, Screening |
BUY
Exercise of conversion of derivative security
|
Direct |
3,954
+15.16%
|
-
|
|
Feb 25
2025
|
James Herriott SVP, General Counsel & Sec |
SELL
Payment of exercise price or tax liability
|
Direct |
775
-5.64%
|
$39,525
$51.28 P/Share
|
|
Feb 25
2025
|
James Herriott SVP, General Counsel & Sec |
BUY
Exercise of conversion of derivative security
|
Direct |
1,647
+10.71%
|
-
|
|
Feb 25
2025
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Payment of exercise price or tax liability
|
Direct |
2,008
-10.12%
|
$102,408
$51.28 P/Share
|
|
Feb 25
2025
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
3,954
+16.62%
|
-
|
|
Feb 25
2025
|
Sarah Condella EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
1,859
-2.32%
|
$94,809
$51.28 P/Share
|
|
Feb 25
2025
|
Sarah Condella EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
3,954
+4.69%
|
-
|
|
Feb 20
2025
|
James Herriott SVP, General Counsel & Sec |
SELL
Payment of exercise price or tax liability
|
Direct |
1,531
-11.24%
|
$76,550
$50.48 P/Share
|
|
Feb 20
2025
|
James Herriott SVP, General Counsel & Sec |
BUY
Grant, award, or other acquisition
|
Direct |
3,324
+19.62%
|
-
|
|
Feb 20
2025
|
Sarah Condella EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
2,214
-2.82%
|
$110,700
$50.48 P/Share
|
|
Feb 20
2025
|
Sarah Condella EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
4,805
+5.76%
|
-
|
|
Feb 20
2025
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Payment of exercise price or tax liability
|
Direct |
2,437
-13.3%
|
$121,850
$50.48 P/Share
|
|
Feb 20
2025
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
4,805
+20.77%
|
-
|
|
Feb 20
2025
|
Jacob A Orville EVP, GM, Screening |
SELL
Payment of exercise price or tax liability
|
Direct |
2,225
-10.9%
|
$111,250
$50.48 P/Share
|
|
Feb 20
2025
|
Jacob A Orville EVP, GM, Screening |
BUY
Grant, award, or other acquisition
|
Direct |
4,805
+19.06%
|
-
|
|
Feb 20
2025
|
Kevin T Conroy President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,140
-1.87%
|
$1,057,000
$50.48 P/Share
|
|
Feb 20
2025
|
Kevin T Conroy President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
48,044
+4.08%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 125K shares |
|---|---|
| Exercise of conversion of derivative security | 93K shares |
| Open market or private purchase | 19.5K shares |
| Payment of exercise price or tax liability | 51.2K shares |
|---|---|
| Open market or private sale | 35.8K shares |